CA2850579A1 - Method for improving the stability of purified factor viii after reconstitution - Google Patents
Method for improving the stability of purified factor viii after reconstitution Download PDFInfo
- Publication number
- CA2850579A1 CA2850579A1 CA2850579A CA2850579A CA2850579A1 CA 2850579 A1 CA2850579 A1 CA 2850579A1 CA 2850579 A CA2850579 A CA 2850579A CA 2850579 A CA2850579 A CA 2850579A CA 2850579 A1 CA2850579 A1 CA 2850579A1
- Authority
- CA
- Canada
- Prior art keywords
- factor viii
- molecule
- fviii
- proteolytic cleavage
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960000301 factor viii Drugs 0.000 title claims abstract description 336
- 238000000034 method Methods 0.000 title claims abstract description 59
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 342
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 340
- 230000006337 proteolytic cleavage Effects 0.000 claims abstract description 66
- 239000012634 fragment Substances 0.000 claims abstract description 32
- 238000001990 intravenous administration Methods 0.000 claims abstract description 27
- 238000010253 intravenous injection Methods 0.000 claims abstract description 24
- 238000000746 purification Methods 0.000 claims abstract description 17
- 238000004108 freeze drying Methods 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 102000002110 C2 domains Human genes 0.000 claims abstract description 3
- 108050009459 C2 domains Proteins 0.000 claims abstract description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 165
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 155
- 150000001413 amino acids Chemical class 0.000 claims description 116
- 230000000694 effects Effects 0.000 claims description 93
- 208000009292 Hemophilia A Diseases 0.000 claims description 35
- 241000699670 Mus sp. Species 0.000 claims description 32
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 31
- 108010089996 B-domain-deleted factor VIII Proteins 0.000 claims description 27
- 238000003860 storage Methods 0.000 claims description 24
- 238000003556 assay Methods 0.000 claims description 21
- 101100145421 Prochlorococcus marinus (strain SARG / CCMP1375 / SS120) rpoB gene Proteins 0.000 claims description 20
- 230000000415 inactivating effect Effects 0.000 claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 19
- 108090000190 Thrombin Proteins 0.000 claims description 18
- 238000003776 cleavage reaction Methods 0.000 claims description 18
- 230000007017 scission Effects 0.000 claims description 18
- 229960004072 thrombin Drugs 0.000 claims description 18
- 230000002779 inactivation Effects 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 238000007920 subcutaneous administration Methods 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 238000012032 thrombin generation assay Methods 0.000 claims description 13
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 102000057593 human F8 Human genes 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 229960000900 human factor viii Drugs 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 4
- 230000002439 hemostatic effect Effects 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000003186 pharmaceutical solution Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 106
- 229940024606 amino acid Drugs 0.000 description 105
- 210000002381 plasma Anatomy 0.000 description 47
- 230000037396 body weight Effects 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 24
- 229940031675 advate Drugs 0.000 description 22
- 108010025139 recombinant factor VIII SQ Proteins 0.000 description 22
- 239000000872 buffer Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 208000032843 Hemorrhage Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 14
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 14
- 208000034158 bleeding Diseases 0.000 description 14
- 231100000319 bleeding Toxicity 0.000 description 14
- 230000000740 bleeding effect Effects 0.000 description 14
- 239000003114 blood coagulation factor Substances 0.000 description 14
- 230000036470 plasma concentration Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 238000010254 subcutaneous injection Methods 0.000 description 10
- 239000007929 subcutaneous injection Substances 0.000 description 10
- 102100036537 von Willebrand factor Human genes 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 6
- 239000003593 chromogenic compound Substances 0.000 description 6
- 229940083810 helixate Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 238000007820 coagulation assay Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- -1 Cu2+ and Zn2+ Chemical class 0.000 description 4
- 108010048049 Factor IXa Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940019700 blood coagulation factors Drugs 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 206010059484 Haemodilution Diseases 0.000 description 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108090000054 Syndecan-2 Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002947 procoagulating effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000015957 Acquired Von Willebrand disease Diseases 0.000 description 1
- 208000033316 Acquired hemophilia A Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 206010051012 Gastric varices Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 208000032182 acquired hemophilia B Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 208000014759 blood platelet disease Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 231100000607 toxicokinetics Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548601P | 2011-10-18 | 2011-10-18 | |
| EP11185651.4 | 2011-10-18 | ||
| US61/548,601 | 2011-10-18 | ||
| EP11185651 | 2011-10-18 | ||
| PCT/EP2012/070701 WO2013057219A1 (en) | 2011-10-18 | 2012-10-18 | Method for improving the stability of purified factor viii after reconstitution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2850579A1 true CA2850579A1 (en) | 2013-04-25 |
Family
ID=48140377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2850579A Abandoned CA2850579A1 (en) | 2011-10-18 | 2012-10-18 | Method for improving the stability of purified factor viii after reconstitution |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US9394353B2 (enExample) |
| EP (1) | EP2768853A1 (enExample) |
| JP (2) | JP2014531910A (enExample) |
| KR (1) | KR20140084208A (enExample) |
| CN (1) | CN103917554B (enExample) |
| AU (1) | AU2012318292B2 (enExample) |
| CA (1) | CA2850579A1 (enExample) |
| HK (1) | HK1198541A1 (enExample) |
| WO (1) | WO2013057219A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103917554B (zh) | 2011-10-18 | 2017-03-08 | 杰特有限公司 | 用于改善重构后纯化的因子viii的稳定性的方法 |
| ES2926798T3 (es) * | 2013-03-15 | 2022-10-28 | Bioverativ Therapeutics Inc | Formulaciones de polipéptido de factor VIII |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| CN106456720A (zh) * | 2014-04-01 | 2017-02-22 | 爱德技术生物科学有限公司 | 在无钙作为赋形剂下因子viii的稳定性 |
| US9907835B2 (en) * | 2014-04-01 | 2018-03-06 | Advanced Bioscience Farmacêutica LTDA | Stable Factor VIII formulations with low sugar-glycine |
| DK3193911T5 (da) * | 2014-07-25 | 2024-10-14 | Csl Behring Gmbh | Forbedrede faktor VII-præparater til brug ved behandling af hæmofili A |
| JP6516829B2 (ja) * | 2014-08-04 | 2019-05-22 | シーエスエル、リミテッド | 第ｖｉｉｉ因子製剤 |
| KR102219859B1 (ko) * | 2016-06-24 | 2021-02-25 | 재단법인 목암생명과학연구소 | 재조합 단쇄 fviii 및 그 화학 접합물 |
| JP6877469B2 (ja) | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| KR20200057051A (ko) | 2017-09-27 | 2020-05-25 | 시질론 테라퓨틱스, 인크. | 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소 |
| WO2019074886A1 (en) | 2017-10-09 | 2019-04-18 | Terumo Bct Biotechnologies, Llc | LYOPHILIZATION CONTAINER AND METHOD OF USE |
| WO2019195056A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| CN112203646A (zh) | 2018-04-04 | 2021-01-08 | 西吉隆医疗股份有限公司 | 可植入颗粒和相关方法 |
| CN117467019A (zh) * | 2018-05-18 | 2024-01-30 | 郑州晟斯生物科技有限公司 | 改进的fviii融合蛋白及其应用 |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| EP3736286A1 (en) | 2019-05-09 | 2020-11-11 | Biotest AG | Single chain factor viii molecule |
| EP4061942A4 (en) | 2019-11-22 | 2023-12-20 | Sigilon Therapeutics, Inc. | MONOCLONAL CELL LINES EXPRESSING AN EXOGENEOUS SUBSTANCE AND THEIR USES |
| CN120659872A (zh) | 2022-10-11 | 2025-09-16 | 西吉隆医疗股份有限公司 | 用于治疗疾病的经工程化的细胞和可植入元件 |
| WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| MX9203440A (es) | 1985-04-12 | 1992-07-01 | Genetics Inst | Proteinas procoagulantes novedosas. |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| IL84168A0 (en) | 1986-10-15 | 1988-03-31 | Rorer Int Overseas | Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same |
| JP2872255B2 (ja) | 1987-01-30 | 1999-03-17 | バイオジエン，インコーポレイティド | ファクター▲ｖｉｉｉ▼の高収量生産法 |
| EP0294910B1 (en) | 1987-06-12 | 1996-09-11 | Immuno Ag | Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| PT1754718E (pt) | 1996-04-24 | 2011-07-13 | Univ Michigan | Factor viii resistente à inactivação |
| WO2000024759A1 (en) | 1998-10-23 | 2000-05-04 | The Trustees Of The University Of Pennsylvania | Systemic delivery of gene products via skin |
| EP1194161B1 (en) | 1999-07-13 | 2005-11-23 | Biovitrum Ab | Stable factor viii compositions |
| DK1266006T3 (da) | 2000-03-22 | 2006-01-16 | Octagene Gmbh | Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier |
| AU2002312660A1 (en) * | 2001-05-31 | 2002-12-16 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
| CA2450125A1 (en) | 2001-06-15 | 2002-12-27 | Andre C. Schuh | Gene therapy for hemophilia a |
| US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| SI1624891T2 (sl) | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| US20080070251A1 (en) | 2006-06-30 | 2008-03-20 | Kaufman Randal J | Method of Producing Factor VIII Proteins by Recombinant Methods |
| WO2008077616A1 (en) * | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| EP2411024A4 (en) * | 2009-03-24 | 2013-02-27 | Bayer Healthcare Llc | Variants of factor viii and associated methods of use |
| EP2467166A2 (en) | 2009-08-20 | 2012-06-27 | CSL Behring GmbH | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| GB0915480D0 (en) | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
| CN103917554B (zh) | 2011-10-18 | 2017-03-08 | 杰特有限公司 | 用于改善重构后纯化的因子viii的稳定性的方法 |
| US9534029B2 (en) | 2012-10-03 | 2017-01-03 | Csl Behring Ag | Method of purifying proteins |
-
2012
- 2012-10-18 CN CN201280051574.0A patent/CN103917554B/zh active Active
- 2012-10-18 CA CA2850579A patent/CA2850579A1/en not_active Abandoned
- 2012-10-18 KR KR1020147013298A patent/KR20140084208A/ko not_active Ceased
- 2012-10-18 US US14/351,513 patent/US9394353B2/en active Active
- 2012-10-18 JP JP2014536237A patent/JP2014531910A/ja not_active Withdrawn
- 2012-10-18 WO PCT/EP2012/070701 patent/WO2013057219A1/en not_active Ceased
- 2012-10-18 AU AU2012318292A patent/AU2012318292B2/en active Active
- 2012-10-18 HK HK14112047.2A patent/HK1198541A1/xx unknown
- 2012-10-18 EP EP12772987.9A patent/EP2768853A1/en not_active Ceased
-
2016
- 2016-05-17 US US15/156,744 patent/US9956269B2/en not_active Expired - Fee Related
-
2017
- 2017-02-17 JP JP2017027545A patent/JP2017114889A/ja active Pending
-
2018
- 2018-02-20 US US15/899,510 patent/US10537616B2/en active Active
-
2019
- 2019-12-03 US US16/701,468 patent/US10881717B2/en not_active Expired - Fee Related
-
2020
- 2020-12-02 US US17/109,366 patent/US11510968B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1198541A1 (en) | 2015-05-15 |
| US11510968B2 (en) | 2022-11-29 |
| US20190038722A1 (en) | 2019-02-07 |
| JP2017114889A (ja) | 2017-06-29 |
| AU2012318292B2 (en) | 2015-08-20 |
| WO2013057219A1 (en) | 2013-04-25 |
| US20140249086A1 (en) | 2014-09-04 |
| US10537616B2 (en) | 2020-01-21 |
| EP2768853A1 (en) | 2014-08-27 |
| US20200268854A1 (en) | 2020-08-27 |
| JP2014531910A (ja) | 2014-12-04 |
| KR20140084208A (ko) | 2014-07-04 |
| US10881717B2 (en) | 2021-01-05 |
| AU2012318292A1 (en) | 2013-05-02 |
| US20210308229A1 (en) | 2021-10-07 |
| CN103917554B (zh) | 2017-03-08 |
| US9956269B2 (en) | 2018-05-01 |
| CN103917554A (zh) | 2014-07-09 |
| US9394353B2 (en) | 2016-07-19 |
| US20160367641A1 (en) | 2016-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11510968B2 (en) | Method for improving the stability of purified Factor VIII after reconstitution | |
| JP6250282B2 (ja) | 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子 | |
| US9107902B2 (en) | Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders | |
| JP5832285B2 (ja) | 延長されたインビボ半減期を有する第ｖｉｉｉ因子、フォン・ヴィレブランド因子又はそれらの複合体 | |
| ES2657291T3 (es) | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro | |
| KR20090102795A (ko) | 연장된 생체내 반감기를 갖는 변형된 응고 인자 | |
| RS66972B1 (sr) | Metode lečenja hemofilije a | |
| US12559569B2 (en) | Methods of treating bleeding disorders by administration of chimeras comprising anti-von Willebrand factor antibodies and clotting factors | |
| US20220259287A1 (en) | Single chain factor viii molecule | |
| CN119654164A (zh) | 凝血因子x激活剂及其用于治疗出血性疾病的制剂 | |
| AU2015258240A1 (en) | Method of improving the stability of purified factor viii after reconstitution | |
| US20230190881A1 (en) | Subcutaneous administration of factor viii | |
| EP3785726A1 (en) | Factor viii protein with increased half-life | |
| HK40079628A (en) | Subcutaneous administration of factor viii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170918 |
|
| FZDE | Discontinued |
Effective date: 20211115 |